Perspectives of Oncology Nursing and Investigational Pharmacy in Oncology Research

被引:4
作者
Black, Lora [1 ]
Kulkarni, Darshan [2 ]
机构
[1] Sanford Res, 2301 E 60th St N, Sioux Falls, SD 57104 USA
[2] Kulkarni Law Firm PC, Philadelphia, PA USA
关键词
Investigational drug; Research pharmacy; Research infusions; Clinical trial drug management; Clinical trial pharmacy; Study drug;
D O I
10.1016/j.soncn.2020.151004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: This article will provide an overview of the purpose, structure, and function of an investigational pharmacy in oncology clinical research. It will also discuss the role of the oncology nurse in managing investigational drugs (ID) when caring for a patient receiving treatment on a clinical trial and the importance of their role in the trial process. Data Sources: Government regulations, professional guidelines, and best practices. Conclusion: ID management for clinical trials is a multidisciplinary process requiring input from various professionals to ensure safe, accurate, and study-specific administration. The nurse's role in the process of clinical trial ID management is dependent on each institution's expectations of clinical research nurses and the scope of their role. Implications for Nursing Practice: Multiple nursing roles may be involved in caring for patients who are being treated as part of a clinical trial, including clinical research nurses, infusion nurses, or as nurses providing direct patient care (inpatient or outpatient). Providing education on ID management, specific to the nurse's involvement, is a responsibility of the study team. Ensuring proper safeguards, accurate and protocol-specific delivery and documentation of ID, and completion of patient education are key in the conduct of oncology clinical research. (C) 2020 Published by Elsevier Inc.
引用
收藏
页数:5
相关论文
共 17 条
  • [1] Burdick R, 2017, PROCESS DESIGN STAGE
  • [2] Christou L., 2019, USUAL CAUSES PHARM C
  • [3] Cummings D.J., PLAN DO CHECK ACT TO
  • [4] Hematology/Oncology Pharmacy Association, HOPA INV DRUG SERV B
  • [5] The Role of the Data and Safety Monitoring Board in a Clinical Trial: The CRISIS Study
    Holubkov, Richard
    Casper, T. Charles
    Dean, J. Michael
    Anand, K. J. S.
    Zimmerman, Jerry
    Meert, Kathleen L.
    Newth, Christopher J. L.
    Berger, John
    Harrison, Rick
    Willson, Douglas F.
    Nicholson, Carol
    [J]. PEDIATRIC CRITICAL CARE MEDICINE, 2013, 14 (04) : 374 - 383
  • [6] Institute for Safe Medication Practices, 2018, INV DRUGS STRAT SPON
  • [7] Moore C.M.V., 2012, Quality by Design - FDA Lessons Learned and Challenges for International Harmonization
  • [8] Oncology Nursing Society, 2016, ONC CLIN TRIALS NURS
  • [9] Snipes J, TEMPLATE CLIN TRIAL
  • [10] Tague NancyR., 2005, Plan-Do-Study-Act cycle, V2nd, P390